| CA: Schedule II
DE: Anlage II (Prohibited)
UK: Under Psychoactive Substances Act
US: Schedule I|
5F-PB-22 (5F-QUPIC or Quinolin-8-yl 1-pentyfluoro-1H-indole-3-8-carboxylate) is a designer drug which acts as a cannabinoid agonist. The structure of 5F-PB-22 appears to have been designed with an understanding of structure-activity relationships within the indole class of cannabinoids.
5F-PB-22 acts as a full agonist with a binding affinity of 0.468nM at CB1 and 0.633nM at CB2 cannabinoid receptors.
As of October 2015 5F-PB-22 is a controlled substance in China.
In January 2014, 5F-PB-22 was designated as a Schedule I controlled substance in the United States after several deaths were associated with its use.
In the United Kingdom (as of May 2016), previously unregulated substances deemed to be psychoactive are now controlled by the Psychoactive Substances Act. Consequently, the sale, distribution, import, and purchase of 5F-PB-22 is banned.